SCHEMBL3532946

SCHEMBL3532946

Cc1cccc(NC(=O)Nc2ccc(-c3coc4c(-c5cncnc5)cnc(N)c34)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.69
AURKB Q96GD4 8/20 0.69
FLT1 P17948 7/20 0.69
FLT3 P36888 7/20 0.69
LCK P06239 6/20 0.69
CSF1R P07333 6/20 0.69
LYN P07948 6/20 0.69
BLK P51451 6/20 0.69
ROCK2 O75116 5/20 0.69
MAP4K4 O95819 5/20 0.69
RET P07949 5/20 0.69
RPS6KB1 P23443 5/20 0.69
FRK P42685 5/20 0.69
CLK2 P49760 5/20 0.69
NEK2 P51955 5/20 0.69
CSNK1G2 P78368 5/20 0.69
HIPK4 Q8NE63 5/20 0.69
SLK Q9H2G2 5/20 0.69
PLK3 Q9H4B4 5/20 0.69
CLK4 Q9HAZ1 5/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530956 0.93 FLT1 (0.77) KDRAURKBFLT1FLT3LCK
SCHEMBL3526116 0.92 KDR (0.67) KDRAURKBFLT1FLT3LCK
SCHEMBL3528701 0.90 KDR (0.68) KDRAURKBFLT1FLT3LCK
SCHEMBL3528557 0.88 KDR (0.63) KDRAURKBFLT1FLT3LCK
SCHEMBL3527107 0.88 KDR (0.63) KDRAURKBFLT1FLT3LCK
SCHEMBL3533520 0.88 KDR (0.63) KDRAURKBFLT1FLT3LCK
SCHEMBL3531374 0.87 KDR (0.68) KDRAURKBFLT1FLT3LCK
SCHEMBL3534338 0.86 KDR (0.64) KDRAURKBFLT1FLT3LCK
SCHEMBL3531671 0.85 KDR (0.61) KDRAURKBFLT1FLT3LCK
SCHEMBL3530386 0.85 KDR (0.59) KDRAURKBFLT1FLT3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.